Assessment cycle 2024 Q1 — page 2
Documents ratified in the 2024 Q1 assessment cycle, which ran from 1 January 2024 to 31 March 2024 and was ratified on 18 March 2024.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 731 participants over 48 weeks. Primary result: A dose-dependent…
Moderate22 Feb 2025 -
Diagnostic accuracy study of Gonadorelin in gh axis over single test. Primary result: An established diagnostic stimulation test. The Institute records that the…
Moderate22 Sep 2024 -
Single-arm open-label study of Gonadorelin in gh axis over months. Primary result: Effective when delivered by pump at a physiological pulse frequency. Non-pulsatile…
Moderate12 Jul 2024 -
Diagnostic accuracy study of Sermorelin in gh axis over single test. Primary result: Formerly marketed as a diagnostic agent; withdrawn for commercial reasons.
Moderate11 Nov 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in obesity randomising 592 participants over 52 weeks. Primary result: Mean change…
Low12 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over 52 weeks. Primary result: A smaller weight effect than in…
Low08 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low15 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Jul 2024 -
Single-arm open-label, phase 3 study of Tirzepatide in sleep apnoea and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low29 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low26 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low31 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Jun 2024 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Dec 2024 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Feb 2025 -
Observational, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Oct 2024 -
Randomised, double-blind, placebo-controlled study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 May 2024 -
Single-arm open-label study of Semax in cognition over open-label extension of the parent trial. The Institute holds no reported primary result for this record and…
Very low16 Jul 2024 -
Randomised crossover, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low15 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Oct 2024 -
Randomised crossover, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Oct 2024 -
Randomised crossover, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low24 Apr 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Observational, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low09 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 May 2024 -
Single-arm open-label, phase 2 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low20 Jan 2025 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Aug 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Nov 2024
page 2 of 3